• 3 of 3

Figure 2: Meta-analysis of phase II/III studies for potential cardiovascular risk

Guidance for industry diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

Source  United States Department of Health and CDER